DUBLIN – January 27, 2021 – Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of...
Read More
€50,000 award goes to University Hospital of Lille in France to fund research into the potential impact of Extracorporeal Photopheresis (ECP) on fibrosing processes DUBLIN, August 31, 2020 -- Mallinckrodt...
Read More
In a rare dual-review process, two independent advisory committees to the Australian Minister for Health recommend reimbursement based on a favorable clinical and cost-effectiveness comparison STAINES-UPON-THAMES, United Kingdom and LAKEWOOD,...
Read More
Approval marks first combined indication label and first regulatory approval in the world for UVADEX in conjunction with the THERAKOS Extracorporeal Photopheresis (ECP) System for the treatment of chronic GvHD...
Read More
2020 award open for entries for a chance to win €50,000 -- Investigator Award recognises individuals making a difference and reinforces company's ongoing commitment to the science of immunomodulation through...
Read More
Retrospective study shows that ECP when added to standard local therapy improves survival probability by approximately 30% in lung transplant patients diagnosed with BOS compared to matched controls -- Adjunct...
Read More
€50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust STAINES-UPON-THAMES, England, March 26, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today...
Read More
Collaboration with experts in photopheresis field expected to further enhance understanding of photopheresis' effect on immune modulation across a range of severe and critical conditions Agreement includes joint development activities...
Read More
Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol BEDMINSTER, N.J., Feb. 20, 2019 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE:MNK), a leading global...
Read More
€50,000 award goes to Rotherham NHS Foundation Trust Department of Haematology STAINES-UPON-THAMES, England, March 20, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the inaugural recipient of its...
Read More